Publications by authors named "Boue D"

Background: The outcome for pediatric patients with high-grade glioma (HGG) remains poor. Veliparib, a potent oral poly(adenosine diphosphate-ribose) polymerase (PARP) 1/2 inhibitor, enhances the activity of radiotherapy and DNA-damaging chemotherapy.

Methods: We conducted a single-arm, non-randomized phase 2 clinical trial to determine whether treatment with veliparib and radiotherapy, followed by veliparib and temozolomide, improves progression-free survival in pediatric patients with newly diagnosed HGG without H3 K27M or BRAF mutations compared to patient level data from historical cohorts with closely matching clinical and molecular features.

View Article and Find Full Text PDF
Article Synopsis
  • Increased access to genomic profiling in pediatric cancer has improved the identification of genetic variations linked to cancer risk, particularly highlighting Noonan syndrome (NS) and its connection to gliomas and glioneuronal tumors.
  • In a study of 314 pediatric cancer patients, 1.3% were found to have germline variants associated with NS, with a significant portion showing these variants linked to glioma diagnoses.
  • The research not only confirmed existing associations but also led to the discovery of NS in previously undiagnosed patients, underscoring the value of genomic profiling in recognizing complex genetic conditions related to cancer.
View Article and Find Full Text PDF

Acute promyelocytic leukemia (APL) with variant RARA translocation is linked to over 15 partner genes. Recent publications encompassing 6 cases have expanded the spectrum of RARA partners to torque teno mini virus (TTMV). This entity is likely underrecognized due to the lack of clinician and pathologist familiarity, inability to detect the fusion using routine testing modalities, and informatic challenges in its recognition within next-generation sequencing (NGS) data.

View Article and Find Full Text PDF
Article Synopsis
  • A multicenter phase II trial evaluated the effectiveness of adding vorinostat or bevacizumab to focal radiation therapy (RT) in improving 1-year event-free survival (EFS) for children with newly diagnosed high-grade gliomas (HGGs), compared to the standard treatment of temozolomide.
  • Out of 90 patients, the one-year EFS rates were 43.8% for bevacizumab, 41.4% for vorinostat, and 59.3% for temozolomide, with no significant differences among the treatment options.
  • The study concluded that combining vorinostat or bevacizumab with RT does not offer superior outcomes compared to temoz
View Article and Find Full Text PDF
Article Synopsis
  • - Somatic mosaicism can lead to neurological disorders, like developmental brain malformations and epilepsy, and is typically thought to happen due to genetic changes after fertilization during fetal development.
  • - This research presents a new idea that some brain mosaicism, specifically in patients with focal epilepsy and extra copies of chromosome 1q, could arise from genetic errors during the formation of reproductive cells.
  • - Analysis revealed that these chromosome 1q gains were present only in the brain tissue of patients and not in their blood or buccal cells, particularly affecting astrocytes, which showed unique gene expressions and inclusions linked to epilepsy.
View Article and Find Full Text PDF

Background: Central nervous system (CNS) cancer is the 10th leading cause of cancer-associated deaths for adults, but the leading cause in pediatric patients and young adults. The variety and complexity of histologic subtypes can lead to diagnostic errors. DNA methylation is an epigenetic modification that provides a tumor type-specific signature that can be used for diagnosis.

View Article and Find Full Text PDF

Glioneuronal tumors are a heterogenous group of CNS neoplasms that can be challenging to accurately diagnose. Molecular methods are highly useful in classifying these tumors-distinguishing precise classes from their histological mimics and identifying previously unrecognized types of tumors. Using an unsupervised visualization approach of DNA methylation data, we identified a novel group of tumors (n = 20) that formed a cluster separate from all established CNS tumor types.

View Article and Find Full Text PDF

Medulloblastoma is the most common malignant paediatric brain tumour, with ~30% mediated by Sonic hedgehog signalling. Vismodegib-mediated inhibition of the Sonic hedgehog effector Smoothened inhibits tumour growth but causes growth plate fusion at effective doses. Here, we report a nanotherapeutic approach targeting endothelial tumour vasculature to enhance blood-brain barrier crossing.

View Article and Find Full Text PDF

Rasmussen encephalitis (RE) is a rare childhood neurological disease characterized by progressive unilateral loss of function, hemispheric atrophy and drug-resistant epilepsy. Affected brain tissue shows signs of infiltrating cytotoxic T-cells, microglial activation, and neuronal death, implicating an inflammatory disease process. Recent studies have identified molecular correlates of inflammation in RE, but cell-type-specific mechanisms remain unclear.

View Article and Find Full Text PDF

Diffuse spinal cord gliomas (SCGs) are rare tumors associated with a high morbidity and mortality that affect both pediatric and adult populations. In this retrospective study, we sought to characterize the clinical, pathological, and molecular features of diffuse SCG in 22 patients with histological and molecular analyses. The median age of our cohort was 23.

View Article and Find Full Text PDF

Rhabdoid tumors (RTs) of the brain (atypical teratoid/rhabdoid tumor; AT/RT) and extracranial sites (most often the kidney; RTK) are malignant tumors predominantly occurring in children, frequently those with germline alterations. Here we present data from seven RTs from three pediatric patients who all had multi-organ involvement. The tumors were analyzed using a multimodal molecular approach, which included exome sequencing of tumor and germline comparator and RNA sequencing and DNA array-based methylation profiling of tumors.

View Article and Find Full Text PDF

Ependymal tumors are the third most common brain tumor under 14 years old. Even though metastatic disease is a rare event, it affects mostly young children and carries an adverse prognosis. The factors associated with dissemination and the best treatment approach have not yet been established and there is limited published data on how to manage metastatic disease, especially in patients under 3 years of age.

View Article and Find Full Text PDF

Objective: Epilepsy-associated developmental lesions, including malformations of cortical development and low-grade developmental tumors, represent a major cause of drug-resistant seizures requiring surgical intervention in children. Brain-restricted somatic mosaicism has been implicated in the genetic etiology of these lesions; however, many contributory genes remain unidentified.

Methods: We enrolled 50 children who were undergoing epilepsy surgery into a translational research study.

View Article and Find Full Text PDF

Primary spinal cord tumors contribute to ≤ 10% of central nervous system tumors in individuals of pediatric or adolescent age. Among intramedullary tumors, spinal ependymomas make up ~ 30% of this rare tumor population. A twelve-year-old male presented with an intradural, extramedullary mass occupying the dorsal spinal canal from C6 through T2.

View Article and Find Full Text PDF

Background: Pediatric cancers typically have a distinct genomic landscape when compared to adult cancers and frequently carry somatic gene fusion events that alter gene expression and drive tumorigenesis. Sensitive and specific detection of gene fusions through the analysis of next-generation-based RNA sequencing (RNA-Seq) data is computationally challenging and may be confounded by low tumor cellularity or underlying genomic complexity. Furthermore, numerous computational tools are available to identify fusions from supporting RNA-Seq reads, yet each algorithm demonstrates unique variability in sensitivity and precision, and no clearly superior approach currently exists.

View Article and Find Full Text PDF
Article Synopsis
  • Wnt-activated medulloblastoma (MB) typically has a strong prognosis, but treatment options for relapsed cases are not well-established.
  • Two patients with relapsed Wnt-MB were treated successfully using a combination of marrow-ablative chemotherapy and autologous hematopoietic progenitor cell rescue.
  • The study suggests a multi-disciplinary treatment approach for recurrent Wnt-MB, potentially involving HDCx/AuHPCR and possibly additional re-irradiation.
View Article and Find Full Text PDF

Retinoblastoma is a childhood cancer of the retina involving germline or somatic alterations of the RB Transcriptional Corepressor 1 gene, RB1. Rare cases of sellar-suprasellar region retinoblastoma without evidence of ocular or pineal tumors have been described. A nine-month-old male presented with a sellar-suprasellar region mass.

View Article and Find Full Text PDF

Choroid plexus tumors are rare pediatric neoplasms ranging from low-grade papillomas to overtly malignant carcinomas. They are commonly associated with Li-Fraumeni syndrome and germline mutations. Choroid plexus carcinomas associated with Li-Fraumeni syndrome are less responsive to chemotherapy, and there is a need to avoid radiation therapy leading to poorer outcomes and survival.

View Article and Find Full Text PDF

Recent discoveries have provided valuable insight into the genomic landscape of pediatric low-grade gliomas (LGGs) at diagnosis, facilitating molecularly targeted treatment. However, little is known about their temporal and therapy-related genomic heterogeneity. An adequate understanding of the evolution of pediatric LGGs' genomic profiles over time is critically important in guiding decisions about targeted therapeutics and diagnostic biopsy at recurrence.

View Article and Find Full Text PDF

Meningiomas are a central nervous system tumor primarily afflicting adults, with <1% of cases diagnosed during childhood or adolescence. Somatic variation in NF2 may be found in ∼50% of meningiomas, with other genetic drivers (eg, SMO, AKT1, TRAF7) contributing to NF2 wild-type tumors. NF2 is an upstream negative regulator of YAP signaling and loss of the NF2 protein product, Merlin, results in YAP overexpression and target gene transcription.

View Article and Find Full Text PDF